Going Beyond PD-(L)1 Inhibition: Where Can Manipulating the Immune System take Cancer Care?

Access Course


Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Learn about agents that target pathways in solid tumors other than PD-1/PD-L1


This activity is intended for hematologists/oncologists, nurses, and pharmacists.


The goal of this activity is to improve knowledge regarding immunotherapy pathways beyond programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), and data for agents that target these pathways.


Learning Objectives:

  • Have increased knowledge regarding the common strategies and pathways beyond PD-(L)1 that cancer cells harness to avoid detection by the immune system
  • Have increased knowledge regarding the mechanisms of action (MOAs) of emerging cancer immunotherapies
  • Have increased knowledge regarding the scientific rationale for evaluating and integrating cancer immunotherapy throughout the continuum of care for patients with cancer


Approximate Time to Complete: 30 minutes


Credit Available: Dec. 26, 2019 - Dec. 26, 2020


Developed through a partnership between SITC and Medscape.








View Available Guidelines Here.

Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50
(0.5 contact hours are in the area of pharmacology)
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.50
Accreditation Council for Pharmacy Education
CEU: 0.05
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50